Radicle ACES: A Study of Commercially Available CBD Used in the Real-world Setting (RWE-ACES)
Status
Completed
Conditions
Sleep Disturbance
Anxiety
Pain
Treatments
Other: Commercially available, orally ingestible CBD product
Study type
Observational
Funder types
Industry
Identifiers
Details and patient eligibility
About
A randomized, open-label study of commercially available, orally ingestible, Cannabidiol (CBD) products used in the real-world setting for pain, sleep, and anxiety.
Full description
Radicle ACES is a real-world evidence study that aims to determine the effect of CBD on overall well-being, anxiety, sleep, and pain over a 28-day period in treatment groups compared to a waitlist control group.
Enrollment
3,000 patients
Sex
All
Ages
21+ years old
Volunteers
Accepts Healthy Volunteers
Inclusion criteria
- Participants must be 21 years of age
- Live in the USA
- Endorse symptoms of anxiety, chronic pain, or sleep disturbances as a primary reason for taking a CBD product
- Must have regular access to a computer, mobile device, and/or the internet to complete surveys
Exclusion criteria
- A person pregnant, trying to become pregnant or breastfeeding
- Anyone diagnosed with liver disease or considered a heavy drinker
- Anyone taking medication that warns against grapefruit consumption
Trial design
3,000 participants in 14 patient groups
Arm A
Description:
Commercially available, orally ingestible CBD product A
Treatment:
Other: Commercially available, orally ingestible CBD product
Arm B
Description:
Commercially available, orally ingestible CBD product B
Treatment:
Other: Commercially available, orally ingestible CBD product
Arm C
Description:
Commercially available, orally ingestible CBD product C
Treatment:
Other: Commercially available, orally ingestible CBD product
Arm D
Description:
Commercially available, orally ingestible CBD product D
Treatment:
Other: Commercially available, orally ingestible CBD product
Arm E
Description:
Commercially available, orally ingestible CBD product E
Treatment:
Other: Commercially available, orally ingestible CBD product
Arm F
Description:
Commercially available, orally ingestible CBD product F
Treatment:
Other: Commercially available, orally ingestible CBD product
Arm G
Description:
Commercially available, orally ingestible CBD product G
Treatment:
Other: Commercially available, orally ingestible CBD product
Arm H
Description:
Commercially available, orally ingestible CBD product H
Treatment:
Other: Commercially available, orally ingestible CBD product
Arm I
Description:
Commercially available, orally ingestible CBD product I
Treatment:
Other: Commercially available, orally ingestible CBD product
Arm J
Description:
Commercially available, orally ingestible CBD product J
Treatment:
Other: Commercially available, orally ingestible CBD product
Arm K
Description:
Commercially available, orally ingestible CBD product K
Treatment:
Other: Commercially available, orally ingestible CBD product
Arm L
Description:
Commercially available, orally ingestible CBD product L
Treatment:
Other: Commercially available, orally ingestible CBD product
Arm M
Description:
Commercially available, orally ingestible CBD product M
Treatment:
Other: Commercially available, orally ingestible CBD product
Control
Description:
Waitlist control
Trial contacts and locations
1
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems